Is NCT06526819 recruiting in San Francisco, CA?

Yes, NCT06526819 is currently recruiting participants at its San Francisco, CA location. This cancer clinical trial is actively enrolling qualified participants.

How do I join the cancer clinical trial in San Francisco?

To join this clinical trial in San Francisco, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this San Francisco clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Cancer Clinical Trial in San Francisco, CA

Who Can Participate

Inclusion Criteria

\- Histologically or cytologically-confirmed cancer that is advanced, recurrent, or metastatic with the following origins, and whose disease progressed on standard therapy and for whom there are no alternative therapies that may confer overall survival benefit. For patients in the Dose Escalation part:

Platinum-resistant ovarian cancer

Histologically diagnosed ovarian, fallopian tube, or primary peritoneal cancer, with predominantly high-grade (Grade 2 or 3) epithelial features (serous and clear cell)

Platinum resistant is defined as relapsed within 6 months after the last dose of platinum-based therapy

Triple negative breast cancer - ER- and PR-negative with HER2 negative

HER2 negative is defined as one of the following: 0 or 1+ by IHC, or if IHC 2+, then in situ hybridization is negative per the ASCO-CAP HER2 guidelines

ER- and PR-negative is defined as \< 10% of cells expressing hormonal receptors by IHC, as per standard guidelines

Squamous cell carcinoma of the anus \- Patient with locally advanced ineligible for surgery is allowed.

Squamous cell carcinoma of the head and neck

Non-small cell lung cancer (NSCLC: adenocarcinoma, large cell, and squamous cell carcinoma)

Uterine serous cancer (recurrent or persistent) For Patients in the Dose Expansion Part:

Cohort A: PROC (same as above)

Cohort B: TNBC (same as above)

Cohort C: SCCA (same as above)

ECOG performance \</= 2 at screening

Recovered from any prior treatment related toxicities

Adequate organ function as evidenced by: a. Hemoglobin \>/= 9 g/dL (transfusion or use of erythropoietin to obtain this are not permitted) b. Absolute neutrophil count \>/= 1500 uL (platelet transfusion not allowed to achieve this) c. Platelet count \>/= 100 x 10 (platelet transfusion not alled to achieve this) d. Bilirubin \</= 1.5 x ULN (or \</= 3.0 x if ULN if Gilbert's syndrome) e. AST and ALT \</= 3.0 x ULN (or \</= 5 x ULN if the liver has tumor involvement f. Calculated creatinine clearance \>/= 60 mL/min using Cockcroft-Gault formula

Patient is non-fertile or agrees to use adequate methods of contraception or agrees to refrain completely from heterosexual intercourse during the study and for 6 months (for female and male patients alike) after the last dose of study intervention.

May be HIV positive if the following conditions are met:

CD4 + T-cell count \>/= 350 cells/uL

HIV viral load \< 400 copies/ml prior to enrollment

No history of acquired immunodefficiency syndrome (AIDS) defining opportunistic infections

Known hepatitis B infection mush have negative serum HbsAg. Patients with known hepatitis C virus infection must have a viral load below the limit of quantification Japan sites only: HBc antibody or HBsantibody tests should be performed if HBsAg is negative. If HBc antibody or HBs antibody tests are positive, HBV DNA quantitative tests should be performed to confirm that HBV DNA is negative.

Exclusion Criteria

Patient has received prior treatment at any time with a cell cycle checkpoint inhibitor (eg, CHK1 and/or CHK2, WEE1, or ATR inhibition)

Patient has a known allergy or sensitivity to any component of SMP-3124LP, including the inactive ingredients

Patient has received treatment with systemic anticancer therapy, radiotherapy, or investigational therapy within 14 days prior to Study Cycle 1 Day 1. (Palliative radiotherapy with a limited field of radiation within 2 weeks will be permitted.)

Patient has undergone a major surgical procedure ≤ 28 days, or minor surgical procedure ≤ 7 days, prior to Cycle 1 Day 1

Patient has used strong CYP1A2 or 2D6 inhibitors within 14 days or 5 half-lives, whichever occurs first, prior to Cycle 1 Day 1 (examples of restricted CYP1A2 and CYP2D6, P-gp, and/or BCRP inducers, inhibitors, or substrates are presented in Table 16)

Patient has central nervous system metastasis or leptomeningeal disease

Prior or concurrent malignancy whose natural history or treatment would have a significant potential to interfere with the safety or efficacy assessments of the investigational regimen

Patient has an abnormal ECG that is clinically significant, including a corrected QT interval (corrected using Fridericia's correction formula \[QTcF\]) \> 470 msec; and/or a history of Torsade de Pointes

Patient has a left ventricular ejection fraction \< 45% by echocardiogram (ECHO)

Patient has clinically significant cardiac disease including heart failure (eg, New York Heart Association, Class III or IV)

Patient has an active, uncontrolled, bacterial, viral, or fungal infection requiring parenteral antimicrobial within 1 weeks prior to Cycle 1 Day 1

Patient is pregnant (as evidenced by a positive serum or urine pregnancy test) or is breastfeeding. Female breastfeeding patients may be enrolled if they interrupt breastfeeding. Breastfeeding should not be resumed for at least 6 months after the last dose of study drug. For sites in Japan only: In addition to the above, any patient deemed likely to be pregnant based on medical interview will be excluded from the study.

Patient with ovarian cancer

Has a history of bowel obstruction related to their underlying disease within 3 months prior to Study Day 1

Has platinum-refractory disease. Platinum refractory is defined as progression during platinum-based chemotherapy

Patient has any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with their participation in the trial or interfere with the interpretation of trial results

Patient is taking a prohibited medication at baseline.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT06526819) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cancer Treatment Options in San Francisco, CA

If you're searching for cancer treatment options in San Francisco, CA, this clinical trial (NCT06526819) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cancer clinical trials near you to find additional studies recruiting in your area.

Cancer Clinical Trial in San Francisco, CA

Expert Care in San Francisco

IRB Approved

No-Cost Care

Apply for This San Francisco Location

Why Participate?

Simple Process

About This Cancer Study in San Francisco